Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -1.92%118.84B | 5.04%29.34B | 0.54%31.02B | -8.70%29.65B | -3.58%28.83B | 6.46%121.17B | -1.79%27.93B | 5.50%30.85B | 16.50%32.48B | 5.85%29.91B |
Cost of revenue | -0.33%104.91B | 6.99%26.22B | 2.48%27.12B | -7.05%26.22B | -2.78%25.35B | 4.81%105.26B | -3.10%24.51B | 2.36%26.46B | 14.29%28.21B | 6.03%26.08B |
Gross profit | -12.41%13.93B | -8.89%3.12B | -11.16%3.9B | -19.56%3.44B | -9.04%3.48B | 18.79%15.91B | 8.78%3.42B | 29.35%4.39B | 33.60%4.27B | 4.65%3.83B |
Operating expense | 6.22%8.36B | 0.92%2.09B | 11.43%2.12B | 7.53%2.09B | 5.47%2.06B | 6.70%7.87B | 11.51%2.07B | 2.15%1.9B | 7.01%1.94B | 6.13%1.96B |
Operating profit | -30.64%5.58B | -23.96%1.03B | -28.38%1.78B | -42.08%1.35B | -24.19%1.42B | 33.58%8.04B | 4.82%1.35B | 62.28%2.49B | 68.42%2.33B | 3.14%1.87B |
Net non-operating interest income (expenses) | 3.95%-170M | -17.50%-47M | -11.90%-47M | 16.33%-41M | 23.91%-35M | 1.67%-177M | 24.53%-40M | 2.33%-42M | -16.67%-49M | -9.52%-46M |
Non-operating interest income | 15.91%102M | 4.00%26M | 3.85%27M | 26.32%24M | 38.89%25M | 44.26%88M | 78.57%25M | 85.71%26M | 11.76%19M | 12.50%18M |
Non-operating interest expense | 2.64%272M | 12.31%73M | 8.82%74M | -4.41%65M | -6.25%60M | 9.96%265M | -2.99%65M | 19.30%68M | 15.25%68M | 10.34%64M |
Net investment income | -0.91%545M | 750.00%187M | 36.43%-164M | -54.33%95M | -26.12%427M | 207.26%550M | -91.91%22M | -414.63%-258M | 405.88%208M | 640.19%578M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 0 | 0 | 0 | ||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | 68.91%-37M | 0.00%-18M | 93.55%-6M | -33.33%-8M | -150.00%-5M | -170.45%-119M | -157.14%-18M | -200.00%-93M | -20.00%-6M | -100.00%-2M |
Less:Other special charges | -68.91%37M | 0.00%18M | -93.55%6M | 33.33%8M | 150.00%5M | 170.45%119M | 157.14%18M | 200.00%93M | 20.00%6M | 100.00%2M |
Other non-operating income (expenses) | -82.80%64M | -121.24%-24M | -11.48%54M | -85.59%17M | -78.75%17M | 160.14%372M | 32.94%113M | 52.50%61M | 293.33%118M | 766.67%80M |
Income before tax | -31.01%5.98B | -21.32%1.12B | -24.92%1.62B | -45.64%1.41B | -26.56%1.83B | 41.61%8.67B | -10.26%1.43B | 36.47%2.16B | 100.08%2.6B | 50.42%2.49B |
Income tax | -23.90%1.94B | -18.94%338M | -19.05%493M | -38.46%464M | -16.10%641M | 35.46%2.54B | -19.81%417M | 30.13%609M | 92.84%754M | 53.11%764M |
Net income | -33.96%4.05B | -22.28%785M | -27.24%1.13B | -48.51%951M | -31.26%1.18B | 44.33%6.13B | -5.52%1.01B | 38.92%1.55B | 103.41%1.85B | 49.26%1.72B |
Net income continuous operations | -33.96%4.05B | -22.30%784M | -27.23%1.13B | -48.57%950M | -31.20%1.18B | 44.33%6.13B | -5.61%1.01B | 39.14%1.55B | 103.19%1.85B | 49.26%1.72B |
Noncontrolling interests | -56.58%475M | -57.14%93M | -56.14%125M | -66.24%106M | -45.68%151M | 69.35%1.09B | 65.65%217M | 73.78%285M | 116.55%314M | 34.95%278M |
Net income attributable to the company | -29.05%3.57B | -12.75%691M | -20.71%1B | -44.91%844M | -28.48%1.03B | 39.86%5.03B | -15.57%792M | 33.16%1.27B | 100.52%1.53B | 52.54%1.44B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -29.05%3.57B | -12.75%691M | -20.71%1B | -44.91%844M | -28.48%1.03B | 39.86%5.03B | -15.57%792M | 33.16%1.27B | 100.52%1.53B | 52.54%1.44B |
Gross dividend payment | ||||||||||
Basic earnings per share | -29.05%357M | -12.75%69.1M | -20.71%100.3M | -44.91%84.4M | -28.48%103.2M | 39.86%503.2M | -15.57%79.2M | 33.16%126.5M | 100.52%153.2M | 52.54%144.3M |
Diluted earnings per share | -29.09%348.15M | -12.75%69.1M | -20.71%100.3M | -44.91%84.4M | -28.45%100.8M | 39.77%490.99M | -15.57%79.2M | 33.16%126.5M | 100.52%153.2M | 52.32%140.87M |
Dividend per share | 0.00%152.41M | -21.43%76.2M | 0 | 37.50%76.2M | 0 | 46.67%152.41M | 64.71%96.99M | 0 | 23.08%55.42M | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |